TACT, the TREAT-NMD Advisory Committee for Therapeutics, is pleased to announce that based on the preliminary review of the applications and inquiries received as of July 15th, the closing date for the fourth TACT review meeting, the following three applications will be reviewed at the TACT meeting scheduled for 15th-16th October 2011 in Lisbon, Portugal:
1) Marc B. Blaustein, MPP, Halo Therapeutics, LLC. Newton, Massachusetts, USA.
A randomised, double-blind, placebo-controlled, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of HT-100 in patients with Duchenne muscular dystrophy.
2) Fabrizio Dolfi, MD, PhD, NicOx SA. Sophia Antipolis, France.
A 6-month multicenter, randomised, double-blind, placebo-controlled, Phase IIa proof of principle study of naproxcinod (HCT 3012) 750 mg bid in patients with Becker Muscular Dystrophy.
3) Chris N Airriess, PhD, California Stem Cell. Irvine, California, USA.
Human Embryonic Stem Cell Derived Motor Neuron Progenitors for the Treatment of Motor Neuron Disease.
As with previous reviews, TACT will generate a detailed report to the applicant within 6 weeks following the meeting. A general 'non-confidential' report summary, developed in collaboration with the applicant, will be available via the TREAT-NMD website within 8 weeks following the meeting at www.treat-nmd.eu/TACT/.
Dates for the subsequent TACT meeting have been confirmed as 28th-29th April 2012 and individuals interested in potentially submitting an application for this meeting should send an expression of interest to the TACT secretariat -
j'avoue ne pas comprendre ,entre l'echec du napro et le thème de l'étude